Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

11.26 -0.44 (-3.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,581,396
Open 11.68
Bid (Size) 10.87 (2)
Ask (Size) 11.55 (4)
Prev. Close 11.70
Today's Range 10.79 - 12.01
52wk Range 3.830 - 17.26
Shares Outstanding 43,219,358
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Altimmune: Q1 Earnings Insights
Altimmune (NASDAQ:ALT) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
+19.15%
+19.15%
1 Month
+123.86%
+123.86%
3 Month
+77.88%
+77.88%
6 Month
+19.15%
+19.15%
1 Year
+20.56%
+20.56%

More News

Read More
Altimmune: Q4 Earnings Insights
Via Benzinga
Altimmune's Earnings Outlook
Via Benzinga
69 Biggest Movers From Yesterday
Via Benzinga
Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know
Via Benzinga
Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity
Via Benzinga
110 Biggest Movers From Friday
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Via Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Via Benzinga
Altimmune Earnings Perspective: Return On Capital Employed
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Via Benzinga
Earnings Scheduled For March 14, 2022
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
Via Talk Markets
ALTIMMUNE INC (ALT) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Via Benzinga
Exposures COVID-19
52 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
33 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off
Via Benzinga
ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34
Via InvestorPlace
Dow Set to Snap Win Streak as Tech Sector Weighs
Via Talk Markets
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.